Biotech Values

[DewDiligence]

OCRX—Do you have a sense what the potential market size could be for this drug?

I previously replied to your question by saying $200M peak annual sales in the US (#msg-111197726). This number is for the IV formulation only, which is the formulation being tested in all of the existing clinical trials.

OCRX’s own peak-sales projection is much higher: $1.5B, consisting of $500-600M from the (existing) IV formulation and $800-900M from the (TBD) oral formulation. Please see slide #25 at http://www.sec.gov/Archives/edgar/data/1274644/000110465915015513/a15-5631_1ex99d1.htm .